Text Size

Mazindol for Cocaine Abuse - 2

This study has been completed.
Sponsor:
Collaborator:
VA Connecticut Healthcare System
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000277
First received: September 20, 1999
Last updated: June 23, 2005
Last verified: December 2002
History of Changes
  Purpose

The purpose of this study is to evaluate high and low dose mazindol for cocaine abuse.


Condition Intervention Phase
Cocaine-Related Disorders
 Drug: Mazindol
 Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Mazindol for Cocaine Abuse

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Side effects
  • Drug use
  • Retention

Estimated Enrollment: 0
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000277

Locations
United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
VA Connecticut Healthcare System
Investigators
Principal Investigator: Thomas R Kosten, M.D. VA Connecticut Healthcare System
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000277     History of Changes
Other Study ID Numbers: NIDA-09250-2, P50-09250-2
Study First Received: September 20, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Mazindol
Central Nervous System Stimulants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
 Therapeutic Uses
Adrenergic Uptake Inhibitors
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Dopamine Uptake Inhibitors
Dopamine Agents

ClinicalTrials.gov processed this record on May 23, 2013